Shanghai Pharmaceuticals (SHA: 601607; SPH) has entered into a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990). The collaboration aims to leverage the advantageous resources of both companies to deepen market access, explore innovative financial payments, and other services for sacituzumab tirumotecan, a TROP2-targeted antibody drug conjugate (ADC) developed by Kelun-Biotech.
Integrating Resources for Enhanced Market Access
Under the partnership, SPH and its subsidiaries, SPH Health Commerce Co., Ltd and MediTrust Health, will offer a range of services including pre-marketing support, utilization of the national holding network, and innovative value-adding services. This comprehensive approach is designed to enhance the market presence and accessibility of sacituzumab tirumotecan within China.
Sacituzumab Tirumotecan’s Global Reach and Recent Approvals
Sacituzumab tirumotecan (SKB264/MK-2870) was the subject of a licensing agreement with Merck, Sharp & Dohme (MSD) in May 2022 for distribution outside Greater China. The drug received marketing approval in China last month, specifically to treat adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have previously undergone at least two kinds of systematic treatment, including at least one for the advanced or metastatic stage.-Fineline Info & Tech
